Twyneo Approval Shakes up Acne Treatment World

Joshua Zeichner, MD, associate professor of dermatology and director of cosmetic & clinical research in dermatology, Mount Sinai Hospital, New York, discusses the impact of the recent FDA approval of Twyneo (Sol-Gel) for the treatment of acne.

Related Videos
Related Content

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

Frontline Forum Part 3: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 23rd 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.